|Dr. Garo H. Armen Ph.D.||Founder, Exec. Chairman & CEO||1.07M||N/A||1953|
|Ms. Christine M. Klaskin||VP of Fin., Principal Financial Officer & Principal Accounting Officer||362.97k||N/A||1966|
|Dr. Marcus Antonius van Dijk Ph.D.||Chief Technology Officer||N/A||N/A||1962|
|Regina Grebla Ph.D.||VP of Investor Relations & Communications||N/A||N/A||N/A|
|John Castle||Head of Translational Medicine & Bioinformatics||N/A||N/A||N/A|
|Ms. Julie DeSander||Chief Bus. Officer||N/A||N/A||N/A|
|Mr. Paulo Moreira||Global Head of Clinical Operations||N/A||N/A||N/A|
|Mr. Dhan Chand||Scientific Director & Head of Drug Discovery||N/A||N/A||N/A|
|Mr. Alfred Dadson||Chief Manufacturing Officer||N/A||N/A||N/A|
|Dr. Steven J. O'Day M.D., Ph.D.||Chief Medical Officer||N/A||N/A||N/A|
Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs comprising Prophage vaccine candidate; AutoSynVax, a synthetic neo-antigen; PhosPhoSynVax, a vaccine candidate to treat tumor; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that is in Phase II clinical trial to treat second line cervical cancer; AGEN1181, an anti-CTLA-4 monospecific antibody that is in Phase 1/2 clinical trial for dose escalation study; AGEN2373, an anti-CD137 monospecific antibody that is in Phase 1 clinical trial; AGEN1223, a novel bispecific antibody to deplete regulatory T cells, which is in a Phase 1 clinical trial; AGEN-1423, a tumor microenvironment conditioning anti-CD73/TGFÃ TRAP bi-functional antibody that has completed Phase 1 clinical trial; AGEN1777, an anti-TIGIT bispecific antibodies; and AGEN1327, an anti-TIGIT monospecific antibody. In addition, it develops INCAGN1876, an anti-GITR monospecific antibody; INCAGN1949, an anti-OX40 monospecific antibody; INCAGN2390, an anti-TIM-3 monospecific antibody; INCAGN2385, an anti-LAG-3 monospecific antibody; and MK-4830, a monospecific antibody targeting ILT4, as well as AGENT 797, an iNKT cells that is in Phase 1 clinical trial for the treatment of COVID-19-related pneumonia; and in preclinical stage to treat multiple myeloma/B cell malignancies and solid tumors. The company has collaborations with Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
Agenus Inc.’s ISS Governance QualityScore as of September 26, 2021 is 9. The pillar scores are Audit: 10; Board: 6; Shareholder Rights: 7; Compensation: 10.